eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
vol. 70
Original paper

Low LATS2 expression is associated with poor prognosis in non-small cell lung carcinoma

Si-Hyong Jang
Mee-Hye Oh
Hyun Deuk Cho
Ji-Hye Lee
Hyun Ju Lee
Hyein Ahn
Han Jo Kim

Department of Pathology, Soonchunhyang University Cheonan Hospital, College of Medicine, Soonchunhyang University, Cheonan, Korea
Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, College of Medicine, Soonchunhyang University, Cheonan, Korea
Pol J Pathol 2019; 70 (3): 189-197
Online publish date: 2019/12/08
Article file
- 05-PJP-01632.pdf  [1.24 MB]
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero


Lung cancer is the leading cause of cancer-related death worldwide, although therapeutic modalities have greatly improved in recent years [1]. Because of the aggressive biological behavior of lung cancer compared to other malignant tumors, the five-year survival rate is still low even with early detection [2, 3]. Histologically, lung carcinoma is divided into two subgroups, small-cell carcinoma and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for approximately 80% of lung cancers and it consists of various histological subtypes including adenocarcinoma, squamous cell carcinoma, large cell carcinoma, large cell neuroendocrine carcinoma and pleomorphic carcinoma [4].
The Hippo pathway is a crucial signaling pathway associated with cell proliferation, apoptosis, and differentiation [5]. Among its core molecules, large tumor suppressor (LATS) is a serine/threonine protein kinase with two well-known homologs, LATS1 and LATS2, which contain an analogous C-terminal region and a dissimilar N-terminal region [6, 7]. LATS biologically functions as a tumor suppressor via the phosphorylation and inactivation of its downstream targets, yes-associated protein and transcriptional co-activator with PDZ-binding motif. LATS2 is frequently downregulated in a number of malignancies including breast, prostate, and lung cancers [8, 9, 10, 11].
A few studies of LATS2 expression in lung cancer have been reported. Low LATS2 mRNA expression led to significant differences in disease-free survival and overall survival in lung adenocarcinoma patients [12]. A previous study that used immunohistochemistry revealed that low LATS2 expression contributed to poor overall survival [9]. However, the relationship between LATS2 expression and variable clinicopathological factors in lung cancer is yet to be clarified. Furthermore, no study has explored the prognostic significance of LATS2 protein expression according to lung cancer subtypes.
Here, we examined the correlations between LATS2 expression levels and a variety of clinicopathological factors in NSCLC patients. We also attempted to establish the value of LATS2 expression as a prognostic marker in the representative lung cancer subtypes, squamous cell carcinoma and adenocarcinoma.

Material and methods

Patients and samples

We enrolled a series of 184 patients with lung cancer: 90 adenocarcinomas, 75 squamous cell carcinomas, 10 large cell neuroendocrine carcinomas, 7 pleomorphic carcinomas and 2 adenosquamous carcinomas. All diagnoses were histologically and immunohistochemically confirmed, and all patients underwent surgical resection at Soonchunhyang University Cheonan Hospital between January 2001 and December 2012.
Tumor tissues were prepared through formalin-fixed and paraffin-embedded processing. We retrospectively reviewed hematoxylin-eosin (H&E) slides and pathological reports as well as other medical records to collect clinicopathological information: patient age, sex, smoking history, tumor size, pleural invasion, lymphovascular invasion, lymph node metastasis and distant metastasis, American Joint Committee on Cancer (AJCC) stage, epidermal growth factor receptor mutation status, recurrence and survival. We restaged lung cancer according to the guidelines of the 8th edition of the AJCC’s cancer staging manual and identified 96 stage I, 43 stage II, 41 stage III and 4 stage IV tumors. Of the patients, 130 were male and 54 were female. Patients were routinely followed up at regular intervals of 6 months or one year after surgery, and the median follow-up period was 39.8 months (range: 0 to 190 months). The mean age at diagnosis was 64.1 years (range: 39 to 82 years old) and the mean tumor size was 3.16 cm. This study was approved by the Institution Review Board of Soonchunhyang University Cheonan Hospital, and informed consent was waived (Institution Review Board no. 2016-07-029). This study conformed to the ethical guidelines of the 1975 Declaration of Helsinki.

Construction of tissue microarray

We constructed the tissue microarrays from formalin-fixed, paraffin-embedded blocks as previously described [13]. We also carefully reviewed the HE slides under light microscopy to select the most representative viable tumor portions. We obtained 2 mm single cores from previously marked tumor areas in donor blocks and transferred them into recipient blocks using trephine (Superbiochips Laboratories, Seoul, Korea).

Immunohistochemistry and interpretation

We purchased rabbit polyclonal anti-LATS2 antibody from Abcam (Abcam, Hong Kong, China, ab70565); we also performed immunohistochemical staining on 4 µm thick sections using the anti-LATS2 as previously described [13]. Briefly, we transferred the tissue microarray sections to adhesive-coated slides and then deparaffinized the slides by heating at 60°C for 1 hour, followed by washing slides three times in xylene. We blocked endogenous peroxidase activity using 5% hydrogen peroxide in methanol for 15 minutes at 37°C and retrieved the antigens using microwave treatment in a pH 6.0 epitope retrieval solution for 20 minutes. We also diluted the anti-LATS2 antibody 1:100 and incubated the sections overnight with the primary antibody in a humidified chamber at 4°C; we treated the secondary antibody using a bond polymer refine detection kit (Leica Biosystem, Wetzlar, Germany) and diaminobenzidine as a chromogen.
Two pathologists (Jang SH and Oh MH) independently evaluated the immunohistochemistry LATS2 results without knowledge of any of the patients’ clinicopathological information. The cytoplasmic staining of tumor cells was classified as negative, weak, moderate or strong immunostaining intensity. Using the proportion results from the different tumor intensity groups, we semi-quantitively evaluated the LATS2 expression level with a H-score system as follows: H-score = 3 × percentage of strongly stained cells + 2 × percentage of moderately stained cells + percentage of weakly stained cells. We divided the cases into two groups, defining low LATS2 expression as an H-score of ≤ 100 and high expression as an H-score >100 (Fig. 1).

Statistical analysis

We performed statistical analyses with SPSS version 14.0 for Windows (SPSS Inc, Chicago, IL, USA), using the χ2 and Pearson’s χ2 tests with linear by linear trends to assess for correlations between LATS2 expression and clinicopathological parameters. We used the Kaplan-Meier method with log-rank test to analyze the overall survival (OS) and disease-free survival (DFS) curves. We also performed univariate and multivariate analyses using Cox proportional hazards regression to examine the prognostic significance of LATS2 expression. P value < 0.05 was considered to be statistically significant.


Correlations between LATS2 expression and clinicopathological data

Forty (21.7%) of the 184 NSCLC specimens showed low LATS2 expression. To examine the impact of low LATS2 expression, we assessed the relationship between LATS2 expression and variable clinicopathological parameters in the 184 patients with NSCLC. There was no statistical difference between LATS2 expression and lung cancer subtypes (p = 0.605). Fifty-six (70.9%) of the 79 recurrent NSCLC patients showed low LATS2 expression and this low LATS2 expression was significantly correlated with disease recurrence (p = 0.047). We also found that low LATS2 expression tended to be correlated with adverse prognostic clinicopathological parameters including, large tumor size (> 3 cm), the presence of vascular and lymphatic invasion, and distant metastasis, although they were not statistically significant (Table I).

Survival analysis in NSCLC patients

At the time of analyses in the present study, disease had recurred in 79 of the 184 patients (42.9%). The Kaplan-Meier DFS curves with log-rank test revealed that patients with high LATS2 expression showed significantly longer OS (p = 0.004) and DFS (p = 0.014) than those with low expression (Fig. 2A, B). We performed univariate and multivariate analyses for all NSCLC patients of LATS2 expression level, sex, age, tumor size, local invasion-associated factors, lymph node metastasis, tumor stage and smoking history. Low LATS2 expression (p = 0.005), sex (p < 0.001), tumor size (p < 0.001), pleural invasion (p = 0.011), vascular invasion (p = 0.043), lymphatic invasion (p = 0.019), lymph node metastasis (p < 0.001), tumor stage (p < 0.001) and smoking history (p = 0.014) were correlated with poor OS based on univariate analysis; low LATS2 expression (p = 0.017), tumor size (p < 0.001), pleural invasion (p < 0.001), lymphatic invasion (p = 0.022), lymph node metastasis (p < 0.001) and tumor stage (p < 0.001) were correlated with significantly poor DFS (Tables II, III). We conducted a multivariate analysis using a Cox proportional regression model to investigate whether low LATS2 expression in NSCLC could be an independent predictor of survival and disease recurrence in the patient. We determined that low LATS2 expression could be an independent predictor of OS (p = 0.032, HR = 1.639) and DFS (p = 0.030, HR = 1.745; Tables II, III).

Survival analysis in squamous cell carcinoma and adenocarcinoma patients

Next, we selected patient groups with two major NSCLC subtypes, squamous cell carcinoma (n = 75) and adenocarcinoma (n = 90), and then assessed the effect of LATS2 expression level on OS and DFS for each subtype. In the squamous cell carcinoma patients, the Kaplan-Meier curves with log-rank test also showed that high LATS2 expression was more favorable for OS (p = 0.144) and DFS (p = 0.022) compared to low LATS2 expression (Fig. 2C, D). In adenocarcinoma patients, Kaplan-Meier disease curve with log-rank test also showed that OS (p = 0.045) and DFS (p = 0.271) of patients with high LATS2 expression was better than those of patients with low LATS2 expression (Fig. 2E, F).


LATS2 on chromosome 13q11-12 is a tumor suppressor gene that encodes a 1046 amino acid protein with a PAPA repeat [8]. In various cancer types, LATS2 is involved in a diverse range of biological functions, including regulating cell cycle, inducing apoptosis and maintaining mitosis integrity [14, 15, 16].
The representative mechanisms of LATS2 inactivation include hypermethylation of the promoter region, tumor-specific mutations and altered upstream microRNA expression, which can trigger tumor development and progression [7, 9, 10, 17]. Various cancer studies have shown a considerable range of decreased LATS2 expression, from 0% to 80% [9, 12, 18, 19, 20]. Additionally, a previous lung cancer study reported that 49.2% (31 of 63) of lung adenocarcinoma and 58.5% (86 of 147) of NSCLC cases showed decreased LATS2 expression through immunohistochemistry. In the present study, low LATS2 expression was observed in 21.7% of NSCLC patients (40 of 184 cases), which is slightly lower than in a previous study. This discordance of LATS2 expression prevalence may be due to the limited number of cases and subtypes of NSCLC enrolled in the studies. Furthermore, each study examined LATS2 expression level based on immunohistochemistry using different interpretation criteria. In the present study, we evaluated LATS2 expression using H-scores because the H-score system could reflect both quantitative and qualitative aspects of immunohistochemical staining results.
Some in vitro studies demonstrated that the down-regulation of LATS2 can lead to promotion of cancer cell growth and migration, which is a phenomenon related to the increase of tumor aggressiveness and invasiveness [9, 12, 20, 21, 22]. Especially in NSCLC cell lines, LATS2 is one of the key molecules associated with tumor growth, epithelial mesenchymal transition and/or invasion/metastasis [9]. Compared to previous studies, we also analyzed more concrete and detailed clinicopathological factors in this study.
Disease relapse, which could represent the tumor growth and invasiveness, was more frequently observed in the low LATS2 expression group than in the high LATS2 expression group. Although not statistically significant, large tumor size (> 3 cm), vascular invasion (p = 0.087) and lymphatic invasion (p = 0.211) also tended to be more frequent in the low LATS2 expression group than in the high LATS2 expression group.
Low LATS2 expression is usually correlated with unfavorable outcomes in a variety of malignancies, such as leukemia, nasopharyngeal cancer, lung cancer and breast cancer [9, 10, 12, 18, 23]. Although some limited reports have been published, the prognostic meaning of LATS2 down-regulation in NSLCL and its major subtypes, especially in squamous cell carcinomas, is not yet clearly established. Previous human lung cancer studies described that in lung adenocarcinomas, the low LATS2 mRNA expression group showed shorter OS and DFS than the high expression group [12], and another recent study demonstrated that low LATS2 immunoreactivity was associated with poor OS in NSCLC [9]. In our study, among all NSCLC cases, those with low LATS2 expression had significantly poorer OS and DFS compared to the high expression group (Tables II, III, Fig. 2A, B). Notably, low LATS2 expression could be considered as an independent prognostic factor in OS and DFS based on multivariate analyses (p = 0.032 and p = 0.030, respectively)
We also analyzed OS and DFS rates for each major NSCLC subtype (squamous cell carcinoma and adenocarcinoma) by LATS2 expression. To further advance the previous clinical study, we included a larger number of variable NSCLC subtypes. Notably, in squamous cell carcinoma, the Kaplan-Meier curve with log-rank test revealed that LATS2 expression was negatively correlated with OS and DFS (Fig. 2C, D). We first demonstrated the prognostic significance of LATS2 expression in lung squamous cell carcinoma. Although there were limitations in the number of samples, statistically significant differences were observed in OS.
The survival curve for adenocarcinoma patients also showed that low LATS2 expression was correlated with poor OS and DFS (p = 0.045 and p = 0.271, respectively), which is similar to results of previous studies. LATS2 is considered to be one of the promising therapeutic targets for malignancy via Hippo pathway modulation. Different methods for generating active LATS variants have been used to enhance LATS kinase activity as a tumor suppressor [24, 25]. Prognosis-predicting and therapeutic-targeting molecules in lung cancer have been mainly identified in adenocarcinomas [26, 27]. In this aspect, discovering novel key molecules involved in tumorigenesis and the progression of lung squamous cell carcinoma would be valuable [28]. LATS2 acts as a novel modulator of therapeutic response in various types of cancers and a potential inducer of apoptosis in a lung cancer cell line [29, 30, 31]. Our data suggest that LATS2 may serve as a potential therapeutic target in both squamous cell carcinoma and adenocarcinoma of the lung.
In conclusion, our findings demonstrated that low LATS2 expression was associated with aggressive clinicopathological features of high NSCLC recurrence rate, tumor growth and invasiveness. Low LATS2 expression was also associated with poor OS and DFS, and was found to be an independent predictor in NSCLC. Furthermore, LATS2 should be considered as a key molecule of tumor development and progression, and it is necessary to assess the possibility of LATS2 as an attractive therapeutic target in NSCLC in both lung squamous cell carcinoma and lung adenocarcinoma.
This work was supported in part by Soonchunhyang University Research Fund.
The authors declare no conflict of interest.


1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Kozu Y, Maniwa T, Takahashi S, et al. Risk factors for both recurrence and survival in patients with pathological stage I non-small-cell lung cancer. Eur J Cardiothorac Surg 2013; 44: e53-58.
3. Hung JJ, Jeng WJ, Chou TY, et al. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma. Ann Surg 2013; 258: 1079-1086.
4. Nakamura H, Saji H. Worldwide trend of increasing primary adenocarcinoma of the lung. Surg Today 2014; 44: 1004-1012.
5. Yu FX, Guan KL. The Hippo pathway: regulators and regulations. Genes Dev 2013; 27: 355-371.
6. Lin XY, Zhang XP, Wu JH, et al. Expression of LATS1 contributes to good prognosis and can negatively regulate YAP oncoprotein in non-small-cell lung cancer. Tumour Biol 2014; 35: 6435-6443.
7. Strazisar M, Mlakar V, Glavac D. LATS2 tumour specific mutations and down-regulation of the gene in non-small cell carcinoma. Lung Cancer 2009; 64: 257-262.
8. Yabuta N, Fujii T, Copeland NG, et al. Structure, expression, and chromosome mapping of LATS2, a mammalian homologue of the Drosophila tumor suppressor gene lats/warts. Genomics 2000; 63: 263-270.
9. Lin CW, Chang YL, Chang YC, et al. MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1. Nat Commun 2013; 4: 1877.
10. Takahashi Y, Miyoshi Y, Takahata C, et al. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 2005; 11: 1380-1385.
11. Powzaniuk M, McElwee-Witmer S, Vogel RL, et al. The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor. Mol Endocrinol 2004; 18: 2011-2023.
12. Luo SY, Sit KY, Sihoe AD, et al. Aberrant large tumor suppressor 2 (LATS2) gene expression correlates with EGFR mutation and survival in lung adenocarcinomas. Lung Cancer 2014; 85: 282-292.
13. Oh MH, Lee HJ, Yoo SB, et al. Clinicopathological correlations of mTOR and pAkt expression in non-small cell lung cancer. Virchows Arch 2012; 460: 601-609.
14. Li Y, Pei J, Xia H, et al. Lats2, a putative tumor suppressor, inhibits G1/S transition. Oncogene 2003; 22: 4398-4405.
15. Ke H, Pei J, Ni Z, et al. Putative tumor suppressor Lats2 induces apoptosis through downregulation of Bcl-2 and Bcl-x(L). Exp Cell Res 2004; 298: 329-338.
16. Aylon Y, Michael D, Shmueli A, et al. A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev 2006; 20: 2687-2700.
17. Jiang Z, Li X, Hu J, Zhou W, et al. Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res 2006; 56: 450-458.
18. Jimenez-Velasco A, Roman-Gomez J, Agirre X, et al. Downregulation of the large tumor suppressor 2 (LATS2/KPM) gene is associated with poor prognosis in acute lymphoblastic leukemia. Leukemia 2005; 19: 2347-2350.
19. Xu B, Sun D, Wang Z, et al. Expression of LATS family proteins in ovarian tumors and its significance. Hum Pathol 2015; 46: 858-867.
20. Yao F, Liu H, Li Z, et al. Down-regulation of LATS2 in non-small cell lung cancer promoted the growth and motility of cancer cells. Tumour Biol 2015; 36: 2049-2057.
21. Furth N, Bossel Ben-Moshe N, Pozniak Y, et al. Down-regulation of LATS kinases alters p53 to promote cell migration. Genes Dev 2015; 29: 2325-2330.
22. Ma B, Cheng H, Gao R, et al. Zyxin-Siah2-Lats2 axis mediates cooperation between Hippo and TGF-beta signalling pathways. Nat Commun 2016; 7: 11123.
23. Zhang Y, Hu CF, Chen J, et al. LATS2 is de-methylated and overexpressed in nasopharyngeal carcinoma and predicts poor prognosis. BMC Cancer 2010; 10: 538.
24. Cook D, Hoa LY, Gomez V, et al. Constitutively active NDR1-PIF kinase functions independent of MST1 and hMOB1 signalling. Cell Signal 2014; 26: 1657-1667.
25. Gomez M, Gomez V, Hergovich A. The Hippo pathway in disease and therapy: cancer and beyond. Clin Transl Med 2014; 3: 22.
26. Gandara DR, Hammerman PS, Sos ML, et al. Squamous cell lung cancer: from tumor genomics to cancer therapeutics. Clin Cancer Res 2015; 21: 2236-2243.
27. Sereno M, Esteban IR, Zambrana F, et al. Squamous-cell carcinoma of the lungs: is it really so different? Crit Rev Oncol Hematol 2012; 84: 327-339.
28. Matsuoka Y, Takagi Y, Nosaka K, et al. Cytoplasmic expression of maspin predicts unfavourable prognosis in patients with squamous cell carcinoma of the lung. Histopathology 2016; 69: 114-120.
29. Mohamed Z, Hassan MK, Okasha S, et al. miR-363 confers taxane resistance in ovarian cancer by targeting the Hippo pathway member, LATS2. Oncotarget 2018; 9: 30053-30065.
30. Song J, Zhao W, Lu C, et al. LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib-mediated death via inhibiting the AMPK-Mfn2 signaling pathway. Cancer Cell Int 2019; 19: 60.
31. Xie Y, Lv Y, Zhang Y, et al. LATS2 promotes apoptosis in non-small cell lung cancer A549 cells via triggering Mff-dependent mitochondrial fission and activating the JNK signaling pathway. Biomed Pharmacother 2019; 109: 679-689.
Copyright: © 2019 Polish Association of Pathologists and the Polish Branch of the International Academy of Pathology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.